Free tool
FAERS Monitor: Keytruda
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125514 or its brand name (Keytruda, Pembrolizumab). Reports on generic versions are filed under their own applications.
Reports
108,520
Serious
95,155
88% of reports
Hospitalization
45,600
Death reported
19,320
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression12,384
- death6,043
- diarrhoea5,920
- fatigue5,236
- off label use4,866
- pyrexia4,018
- rash3,883
- nausea3,672
- product use in unapproved indication3,594
- decreased appetite3,399
- hypertension3,339
- hypothyroidism3,041
- asthenia2,865
- drug ineffective2,660
- interstitial lung disease2,630
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 597 |
| 2015 | 1,281 |
| 2016 | 2,323 |
| 2017 | 4,119 |
| 2018 | 4,867 |
| 2019 | 6,374 |
| 2020 | 6,810 |
| 2021 | 8,400 |
| 2022 | 12,623 |
| 2023 | 15,880 |
| 2024 | 16,087 |
| 2025 | 17,374 |
| 2026 | 11,783 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,945,639 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 12,384 | 26.5 | 26.1 | 268,673 |
| hypothyroidismSignal | 3,041 | 20.3 | 19.6 | 50,536 |
| interstitial lung diseaseSignal | 2,630 | 11.1 | 10.7 | 22,837 |
| hypertensionSignal | 3,339 | 3.1 | 3.0 | 4,686 |
| decreased appetiteSignal | 3,399 | 2.9 | 2.8 | 4,105 |
| product use in unapproved indicationSignal | 3,594 | 2.8 | 2.7 | 4,262 |
| pyrexiaSignal | 4,018 | 2.3 | 2.2 | 2,852 |
| diarrhoea | 5,920 | 1.8 | 1.7 | 2,087 |
| rash | 3,883 | 1.7 | 1.7 | 1,218 |
| asthenia | 2,865 | 1.5 | 1.4 | 451 |
| death | 6,043 | 1.4 | 1.3 | 602 |
| fatigue | 5,236 | 1.3 | 1.3 | 386 |
| off label use | 4,866 | 1.1 | 1.0 | 28 |
| nausea | 3,672 | 0.9 | 0.9 | 43 |
| drug ineffective | 2,660 | 0.4 | 0.4 | 2,702 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.